C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $11.60 Average PT from Brokerages
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The […]
Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The […]
